Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4568463 | 0.90 | MRGPRX4 (0.47) | MRGPRX4 | |
| SCHEMBL4568565 | 0.89 | MRGPRX4 (0.40) | MRGPRX4 | |
| SCHEMBL4568566 | 0.89 | MRGPRX4 (0.40) | MRGPRX4 | |
| SCHEMBL4568568 | 0.85 | MAP2 (0.40) | PTGER1 | |
| SCHEMBL4568207 | 0.83 | MRGPRX4 (0.46) | MRGPRX4PTGER1 | |
| SCHEMBL3703812 | 0.83 | ENPP2 (0.43) | MRGPRX4PTGER1 | |
| SCHEMBL3698683 | 0.83 | TUBB4A (0.46) | MRGPRX4 | |
| SCHEMBL3708494 | 0.82 | TUBB4A (0.50) | MRGPRX4PTGER1 | |
| SCHEMBL3706720 | 0.81 | TUBB4A (0.46) | MRGPRX4 | |
| SCHEMBL3706414 | 0.81 | PPARG (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | PTGER1, CYSLTR1, LTB4R | MRGPRX4 273/4885PTGER1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.